Pharma BD Deal Intelligence
Shire to buy FerroKin BioSciences for up to $325 million, paying a $100 million upfront cash payment plus up to $225 million in post-closing milestones for the…
This acquisition marks an important step for Shire in building a business that serves the growing needs of specialty hematologists and their patients, adding a…
Delaware Chancery Court ordered Shire to pay $45M of FerroKin milestones, finding routine drug-development delays rather than safety issues caused the missed…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Shire acquired FerroKin BioSciences for $100M upfront plus up to $225M in clinical/regulatory/sales milestones. Added Phase 2 oral iron chelator FBS0701 (orphan-designated) to Shire's hematology business.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire plc / FerroKin BioSciences, Inc. (this deal) | 2012 | $325M | 8 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| Shire plc / Baxalta Inc. | 2016 | $32.0B | 77 |
| Shire plc / ViroPharma Incorporated | 2013 | $4.2B | 58 |
← Browse all deals · How we score deals
More: 2012 deals · Shire plc deals · Hematology deals